SCHEDULE: T. Rowe Price Amends Entrada Therapeutics Stake to 0.9%
Beneficial Ownership Report
T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, disclosing a 0.9% beneficial ownership stake in Entrada Therapeutics Inc.
Summary
- T. Rowe Price Associates, Inc. filed an Amendment No. 5 to its Schedule 13G regarding its beneficial ownership in Entrada Therapeutics Inc.
- The filing indicates T. Rowe Price Associates, Inc. beneficially owns 360,526 shares of Entrada Therapeutics Inc. common stock.
- This ownership represents 0.9% of the class of securities.
- T. Rowe Price Associates, Inc. holds sole voting power over 359,103 shares and sole dispositive power over 360,526 shares.
- The reporting person is an investment adviser (IA) based in Maryland.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G Amendment No. 5) by an institutional investor, T. Rowe Price Associates, Inc., indicating a passive stake. It contains factual information about ownership percentages and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Management Comments
- T. Rowe Price Associates, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing is a routine disclosure by an institutional investor, T. Rowe Price Associates, Inc., indicating its passive ownership stake in Entrada Therapeutics Inc. It reflects an investment decision within the biotechnology or pharmaceutical sector, where institutional holdings are common.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming T. Rowe Price's continued, albeit passive, interest in the company.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires filing of this statement |
| 11/14/2025 | Signature date of the filing |
Keywords
Entrada Therapeutics, T. Rowe Price, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.